Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Territorial Tax Parity Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES CORP · Firm: PAMELA BRADLEY
H.R. 1428, The VALID Act NIH Appropriations
Territorial Tax Parity Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES CORP · Firm: PAMELA BRADLEY
H.R. 1428, The VALID Act NIH Appropriations
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ADAPTIVE BIOTECHNOLOGIES CORP via PAMELA BRADLEY
2022 · second_quarter · 2@
2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES CORP via PAMELA BRADLEY
2022 · first_quarter · 1A
Source: Senate LDA
Territorial Tax Parity Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES CORP · Firm: PAMELA BRADLEY
H.R. 1428, The VALID Act NIH Appropriations
Consolidated Appropriations Act, 2022
Client: ADAPTIVE BIOTECHNOLOGIES CORP · Firm: PAMELA BRADLEY
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES CORP via PAMELA BRADLEY
2022 · first_quarter · RR
H.R. 1428, The VALID Act NIH Appropriations
H.R. 1428, The VALID Act NIH Appropriations
H.R. 1428, The VALID Act NIH Appropriations